MK-2206 2HCl is primarily used in research and development, particularly in the field of oncology. It serves as a potent and selective inhibitor of the AKT pathway, which is often dysregulated in various cancers. By targeting AKT, this compound helps in studying the role of this pathway in tumor growth, survival, and resistance to chemotherapy. It is frequently utilized in preclinical studies to evaluate its potential as a therapeutic agent for cancers such as breast, prostate, and lung cancer. Additionally, MK-2206 2HCl is employed in combination therapy research to assess its efficacy when used alongside other anticancer drugs, aiming to enhance treatment outcomes and overcome drug resistance. Its application extends to understanding cellular signaling mechanisms and exploring new strategies for cancer treatment.